These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3674045)

  • 1. Effect of a pharmacy-based cost-containment program on cimetidine costs and use.
    Kong KM; Johnson WF; Anderson PO; Sato LA; Simonian RI
    Am J Hosp Pharm; 1987 Sep; 44(9):2068-73. PubMed ID: 3674045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic surveillance: the results of a clinical pharmacy intervention program.
    Capers CC; Bess DT; Branam AC; Falbe WJ; Mrochek SA; Haymond JD; Stahl AA
    Hosp Pharm; 1993 Mar; 28(3):206-10, 212. PubMed ID: 10124947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of clinical pharmacists to cefazolin utilization.
    Witte KW; Hatoum HT; Hoon TJ
    Hosp Formul; 1987 Aug; 22(8):737-41. PubMed ID: 10283405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy.
    Caldwell RD; Davis SK
    Hosp Pharm; 1987 Dec; 22(12):1205-9. PubMed ID: 10285375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of concurrent monitoring and a preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital.
    Dannenhoffer MA; Slaughter RL; Hunt SN
    Am J Hosp Pharm; 1989 Aug; 46(8):1570-5. PubMed ID: 2773962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost containment through restriction of cephalosporins.
    Britton HL; Schwinghammer TL; Romano MJ
    Am J Hosp Pharm; 1981 Dec; 38(12):1897-900. PubMed ID: 7325168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
    Oh T; Franko TG
    Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidisciplinary cost-containment program promoting less frequent administration of injectable mezlocillin.
    Briceland LL; Nightingale CH; Quintiliani R; Cooper BW
    Am J Hosp Pharm; 1988 May; 45(5):1082-5. PubMed ID: 3400649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Documentation of clinical interactions: quality of care issues and economic considerations in critical care pharmacy.
    Bearce WC; Willey GA; Fox RL; Coleman LT
    Hosp Pharm; 1988 Oct; 23(10):883-4, 886, 889-90. PubMed ID: 10290109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling financial variables--changing prescribing patterns.
    Abramowitz PW
    Am J Hosp Pharm; 1984 Mar; 41(3):503-15. PubMed ID: 6367444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary cost-containment program promoting oral metronidazole for treatment of antibiotic-associated colitis.
    Briceland LL; Quintiliani R; Nightingale CH
    Am J Hosp Pharm; 1988 Jan; 45(1):122-5. PubMed ID: 3348224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pharmacy intervention on aminoglycoside costs.
    Tsuyuki RT; Nakagawa RS
    Can J Hosp Pharm; 1987 Apr; 40(2):51-6. PubMed ID: 10282090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlling moxalactam and cefotaxime use with a target drug program.
    Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG
    Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy to reduce drug expenditures with a drug utilization review program.
    Hoffmann RP
    Hosp Pharm; 1984 Jan; 19(1):7-8, 11-2. PubMed ID: 10264746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacy management strategies for responding to hospital reimbursement changes.
    Curtiss FR
    Am J Hosp Pharm; 1983 Sep; 40(9):1489-92. PubMed ID: 6353913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coping with DRGs: University of California Medical Center, San Diego.
    Lee MP
    Am J Hosp Pharm; 1983 Sep; 40(9):1504-6. PubMed ID: 6414299
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacy-laboratory interactions: a unique method to control antibiotic costs.
    Goff D; Thornton J
    Hosp Pharm; 1989 Jan; 24(1):26-9, 32. PubMed ID: 10291600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monetary incentive for pharmacists to control drug costs.
    Herrick JD; Manning SH
    Am J Hosp Pharm; 1985 Jul; 42(7):1527-32. PubMed ID: 4025348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.